W

ell, this is stunning: Looks like Grail, the Illumina spinout that’s working on an early blood-based screening test for cancer, will be raising a Series B round that clocks in at more than $1 billion.

The company just put out a statement that a number of undisclosed investors are seriously interested in doling out this cash. Fast Company last month had reported that the company was looking to raise $1.7 billion.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Link exchange is nothing else but it is just placing the other person’s website link on your page at appropriate place and other person will also do same in support of you.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.